



SERES
THERAPEUTICS™

Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference

August 2, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 2, 2017-- [Seres Therapeutics, Inc.](#) (NASDAQ:MCRB) today announced it will present at the Canaccord Genuity 37th Annual Growth Conference in Boston, MA on Wednesday, August 9 at 1:00 p.m. ET.

A live audio webcast of the presentation will be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

About Seres Therapeutics

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. Seres' lead program, SER-109, has obtained Breakthrough and Orphan Drug designations from the U.S. Food and Drug Administration and is in Phase 3 development for multiply recurrent *C. difficile* infection. Seres' clinical candidate SER-287 is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis. Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit www.serestherapeutics.com. Follow us on Twitter [@SeresTx](#).



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170802005192/en/>

Source: Seres Therapeutics, Inc.

IR or PR Contact:

Seres Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor Relations and Corporate Communications
Ctanzi@serestherapeutics.com